Treatment Goals in Metastatic EGFR-Positive NSCLC, Advocacy Resources, and Closing Thoughts

Elizabeth Dennis outlines the key factors patients and caregivers should consider when discussing personalized treatment goals with their care team: how treatment may impact daily living, independence, work, and hobbies; emotional support needs and caregiver involvement; and practical factors including transportation, appointment scheduling, work commitments, medication access, insurance coverage, and the ability to sustain treatment adherence over time. The best treatment plan is one that aligns with the patient's medical needs, lifestyle, and individual goals, and communication and education must continue throughout the treatment journey to support that alignment.

Lynn Abbott-McCloud's primary message for patients is to find their lung cancer community. Fellow patients and caregivers who share similar experiences provide a uniquely validating form of support: the experience of being truly understood by others who are living the same reality. She specifically highlights the EGFR Resistors (egfrresistors.org) as a biomarker-specific advocacy community she connects newly diagnosed EGFR-positive patients with immediately, noting that biomarker-specific groups offer the most targeted peer knowledge and support. She encourages patients with any specific biomarker to seek out the corresponding patient advocacy organization.

Elizabeth Dennis closes by emphasizing the provider responsibility to assess the whole patient, ensure informed treatment planning and decision-making, and continuously attend to quality of life as defined by the patient.

Dr. Konduri closes by noting that EGFR-positive lung cancer represents one of the leading examples of actionable genomic alteration-driven treatment in oncology, with treatments that have significantly improved both quality and quantity of life for patients. Active clinical trial research continues to generate newer therapeutic options, and patients are encouraged to ask about trial participation at every line of therapy.